Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Conditions
- Lymphoma
- Primary Central Nervous System Lymphoma
- Recurrent/Refractory Secondary Central Nervous System Lymphoma
Interventions
- DRUG: Buparlisib (BKM120)
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators